Innovations and changes in the ICD‐11 classification of mental, behavioural and neurodevelopmental disorders
…, A Maercker, P Tyrer, A Claudino, E Garralda… - World …, 2019 - Wiley Online Library
Following approval of the ICD‐11 by the World Health Assembly in May 2019, World Health
Organization (WHO) member states will transition from the ICD‐10 to the ICD‐11, with …
Organization (WHO) member states will transition from the ICD‐10 to the ICD‐11, with …
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
…, M de la Mata, M Iñarrairaegui, E Garralda… - Journal of …, 2013 - Elsevier
BACKGROUND & AIMS: Tremelimumab is a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated
antigen 4 (CTLA-4), an inhibitory co-receptor that interferes with T cell …
antigen 4 (CTLA-4), an inhibitory co-receptor that interferes with T cell …
[HTML][HTML] Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
…, L Bazhenova, F De Braud, E Garralda… - … England Journal of …, 2020 - Mass Medical Soc
Background RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers (NSCLCs).
In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …
In patients with RET fusion–positive NSCLC, the efficacy and safety of selective …
Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials.
…, J Tabernero, R Dienstmann, E Garralda - 2018 - ascopubs.org
3032 Background: HPD with ICIs has been recently described as progression disease (PD)
by RECIST with a ≥ two-fold increase in tumor growth rate experimental vs. reference. …
by RECIST with a ≥ two-fold increase in tumor growth rate experimental vs. reference. …
Anti-TIGIT antibody Tiragolumab alone or with Atezolizumab in patients with advanced solid tumors: a phase 1a/1b nonrandomized controlled trial
…, J Bendell, DY Oh, MJ Ahn, E Garralda… - JAMA …, 2023 - jamanetwork.com
Importance Inhibition of the T-cell immunoreceptor with Ig and ITIM domains (TIGIT)/poliovirus
receptor pathway may amplify the antitumor immune response of atezolizumab in …
receptor pathway may amplify the antitumor immune response of atezolizumab in …
[HTML][HTML] Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: a prospective cohort study
…, M Greenhawt, EA Whittaker, E Garralda… - European …, 2022 - Eur Respiratory Soc
Background The long-term sequelae of coronavirus disease 2019 (COVID-19) in children
remain poorly characterised. This study aimed to assess long-term outcomes in children …
remain poorly characterised. This study aimed to assess long-term outcomes in children …
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
Background Oncogenic alterations in RET have been identified in multiple tumour types,
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety, …
including 1–2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety, …
[HTML][HTML] Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation
…, MR Patel, WH Miller Jr, E Garralda… - … England Journal of …, 2023 - Mass Medical Soc
Background Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to
have high potency and selectivity. Methods In a phase 1 study, we evaluated divarasib …
have high potency and selectivity. Methods In a phase 1 study, we evaluated divarasib …
Delivering precision oncology to patients with cancer
With the increasing use of genomic profiling for diagnosis and therapy guidance in many
tumor types, precision oncology is rapidly reshaping cancer care. However, the current …
tumor types, precision oncology is rapidly reshaping cancer care. However, the current …
[HTML][HTML] Caring for patients with cancer in the COVID-19 era
…, J Bergh, I Ernberg, B Besse, F Barlesi, E Garralda… - Nature medicine, 2020 - nature.com
The current COVID-19 pandemic challenges oncologists to profoundly re-organize
oncological care in order to dramatically reduce hospital visits and admissions and therapy-induced …
oncological care in order to dramatically reduce hospital visits and admissions and therapy-induced …